Table 1.
Clinical and pathologic characteristics of patients
| Characteristics | Patients | |
|---|---|---|
| n | % | |
| No. of patients | 218 | 100 |
| Gender | ||
| Male | 160 | 73.39 |
| Female | 58 | 26.61 |
| Age Median (IQR) | 59(52-65) | |
| ≤59 years | 104 | 47.71 |
| >59 years | 114 | 52.29 |
| Histologic type | ||
| Clear cell type | 187 | 85.78 |
| Non-clear cell type | 31 | 14.22 |
| Tumor nucleus grade | ||
| 2 | 109 | 50.00 |
| 3+4 | 109 | 50.00 |
| Initial TNM stage | ||
| Stage I+ II | 120 | 55.05 |
| Stage III+ IV | 98 | 44.95 |
| Pulmonary metastasis | ||
| Present | 134 | 61.47 |
| Absent | 84 | 38.53 |
| Clinical responses | ||
| PR | 48 | 22.02 |
| SD | 113 | 51.83 |
| PD | 57 | 26.15 |
| Metastatic organ number | ||
| 1 | 145 | 66.51 |
| ≥2 | 73 | 33.49 |
| Tumor necrosis | ||
| Present | 73 | 33.49 |
| Absent | 145 | 66.51 |
| IMDC | ||
| Favorable | 37 | 16.97 |
| Intermediate | 143 | 65.60 |
| Poor | 38 | 17.43 |
| Tumor size | ||
| ≤4 cm | 35 | 16.06 |
| >4 and ≤7 cm | 94 | 43.12 |
| >7 and ≤10 cm | 59 | 27.06 |
| >10 cm | 30 | 13.76 |
| Systemic therapy | ||
| Sunitinib | 130 | 59.63 |
| Sorafenib | 88 | 40.37 |
| tPD-L1 | ||
| Negative | 127 | 58.26 |
| Positive | 91 | 41.74 |
| sPD-L1 | ||
| Negative | 148 | 67.89 |
| Positive | 70 | 32.11 |
| PD-1 | ||
| Low | 149 | 68.35 |
| High | 69 | 31.65 |
| Treg | ||
| Low | 140 | 64.22 |
| High | 78 | 35.78 |
| CD8 | ||
| Low | 98 | 44.95 |
| High | 120 | 55.05 |
| CD4 | ||
| Low | 96 | 44.04 |
| High | 122 | 55.96 |
| IS | ||
| Low | 84 | 38.53 |
| Intermediate | 93 | 42.66 |
| High | 41 | 18.81 |
Abbreviations: IQR, interquartile range; PR, partial response; SD, stable disease; PD, progressive disease; tPD-L1, tumor cells PD-L1 expressions; sPD-L1, stromal immune cells PD-L1 expressions; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; IS, Immunoscore.